Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: the 10‐year experience of a single center

References

• Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139–59.
   Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393–7.
   PubMed Web of Science ®Google Scholar
• Lara PNJr, Coe TL, Zhou H, Fernando L, Holland PV, Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Am J Med 1999;107:573–9.
   PubMed Web of Science ®Google Scholar
• von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002;6:320–8.
   PubMedGoogle Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589–600.
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely S, George JN. Quinine-associated thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047–51.
   PubMed Web of Science ®Google Scholar
• Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessner MJ. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002;99:437–42.
   PubMed Web of Science ®Google Scholar
• McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura–hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001;16:202–9.
   PubMed Web of Science ®Google Scholar
• Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60–8.
   PubMed Web of Science ®Google Scholar
• George JN. How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Blood 2000;96:1223–9.
   PubMed Web of Science ®Google Scholar
• Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Transfusion 2004;44:1149–58.
   PubMed Web of Science ®Google Scholar
• Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al.. Cancer-associated hemolytic–uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781–9.
   PubMed Web of Science ®Google Scholar
• Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073–86.
   PubMed Web of Science ®Google Scholar
• Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007;19:148–54.
   PubMed Web of Science ®Google Scholar
• Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286–93.
   PubMed Web of Science ®Google Scholar
• Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993;7:94–103.
   PubMed Web of Science ®Google Scholar
• Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 2006;132:204–9.
   PubMed Web of Science ®Google Scholar
• Dervenoulas J, Tsirigotis P, Bollas G, Pappa V, Xiros N, Economopoulos T, et al.. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000;79:66–72.
   PubMed Web of Science ®Google Scholar
• Pene F, Vigneau C, Auburtin M, Moreau D, Zahar JR, Coste J, et al.. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 2005;31:71–8.
   PubMed Web of Science ®Google Scholar
• Altuntas F, Aydogdu I, Kabukcu S, Kocyigit I, Cikim K, Sari I, et al.. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2007;36:57–67.
   PubMed Web of Science ®Google Scholar
• Teruya J, Styler M, Verde S, Topolsky D, Crilley P. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation. J Clin Apher 2001;16:169–74.
   PubMed Web of Science ®Google Scholar
• Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bambach B, et al.. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation 2004;78:1515–22.
   PubMed Web of Science ®Google Scholar
• George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–5.
   PubMed Web of Science ®Google Scholar
• Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, et al.. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006;81:525–1.
   PubMed Web of Science ®Google Scholar
• Cohen H, Bull HA, Seddon A, Enayat MS, Hill FG, Woolf N, et al.. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989;43:207–14.
   PubMed Web of Science ®Google Scholar
• Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007;40:709–19.
   PubMed Web of Science ®Google Scholar
• Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003;8:375–80.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Int Med 1998;128:541–4.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524–8.
   PubMed Web of Science ®Google Scholar
• Cantrell JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic–uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985;3:723–4.
   PubMed Web of Science ®Google Scholar